FAQs and Forum


If you are a patient or healthcare professional and have a question please post it here. I can’t guarantee I’ll be able to respond to all your questions, but I’ll do my best, especially if the same question comes up frequently.

If you are from a drug company I will only respond if you have found a factual error in our work or you have new information that has been in some way independently verified, that you are willing to put in the public domain about the carbon footprint of your products. If you do have this information though, we’d love to hear from you.

17 thoughts on “FAQs and Forum”

  1. If we acknowledge you as the author, can we use this information to create an adapted document to put on practice website that identifies our local pharmacies involved in the recycling programme and the appropriate person at our practice to contact?
    If you agree we would also like to share the adapted document with other local practices to encourage change locally in Rugby


      1. Hi Alex, this is such a great resource thanks. I am a GP trainee planning to do a QIP on eco-halers. Can I also acknowledge you as an author and use some of the content to create a patient leaflet? Cheers


      2. Hi Greg, a leaflet sounds like a great idea. Would you consider joining the RCGP Climate Advisory Group to share your work?


  2. For Your Information – Are you aware that GSK are now discontinuing the complete the cycle scheme as they ” believe there should be a focus on a wider joint-working approach across the industry, rather than a stand-alone approach”.
    I had recently produced a leaflet regarding recycling inhalers for hospital patients after auditing and finding only 1 out 10 patients returned their inhalers to the pharmacy (the others put in the bin).


    1. Thanks for your message. I had heard. Looks like it’s going to stop in a couple of months. I haven’t got round to updating the site yet.

      Your study sounds interesting. Do you hope to publish? There’s not much known about how patients dispose of inhalers but it’s an important topic.


  3. Hi
    I am a retired GP who does some clinical computer support work for a large 70 000 patient practice in Worcestershire.
    Really interesting website and material. One of the current partners is keen to reduce carbon foot print for medication and we are looking at options – in particular I am keen to not overburden the respiratory nurses where much of this work will fall to and hence am looking ways of fractionating the issue to look for the biggest impact for lowest staff use/hr.
    Hence are you aware of any previous work/resources that allows one to identify the most straightforward swaps with best carbon impact and least financial impact for drug budget. For example I can see that across all 5 sites, we issue approximately 6000 Ventolin evohalers/yr and a straightforward change to Salamol MDI could reduce carbon from approx. 168 tonnes to approx. 35 tonnes with minimal impact on patients in terms of familiarity of device and drug budget.
    That is a very simple example but I have always worked on the basis that simple changes are likely to produce immediate benefit and more complex and across the board changes are difficult to actually get completed!
    Also are you aware of a low carbon respiratory formulary that will meet NICE (assuming patient suitability etc) reduce carbon without bankrupting the drug budget?

    I look forward to any thoughts you might have. Impressed by what you are advocating.

    Best wishes

    Iain Inglis, Bewdley


    1. Hi Iain.

      Thanks for your interest. The website http://www.greener practice.co.uk/inhaler-switch will hopefully be of interest. I should add a link from my site. There is a guide by Dr James Smith that includes a mini formulary.

      Ventolin salamol switch is definitely the easiest and I understand this has even been started at a CCG level in some places.

      In terms of drug budget there is potential to save money by optimising combination treatments, though salbutamol is going to be more expensive.

      Personally I’d like to see much more resource going in to airways disease treatment in terms of time and medicines investment, particularly using combination DPI as maintenance and reliever therapy, that removes the need for salbutamol entirely. I accept this takes more resources though.




  4. Hi Alex,
    I’ve been asked about the cost impact of prescribing DPIs instead of MDIs (which in an ideal wouldn’t be an issue.. but in NHS reality it is). Do you know of any comparative tables?


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s